End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13,920 KRW | -1.49% | 0.00% | -13.75% |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Microbial Analysis
75.6
%
| 3,433 | 84.3 % | 4,216 | 75.6 % | +22.80% |
Property for Rent
16.0
%
| 225 | 5.5 % | 894 | 16.0 % | +297.68% |
DB Provided
4.5
%
| 256 | 6.3 % | 250 | 4.5 % | -2.54% |
Monitoring of Intestinal Microbes, etc.
3.9
%
| 160 | 3.9 % | 215 | 3.9 % | +34.06% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
90.5
%
| 3,665 | 89.9 % | 5,046 | 90.5 % | +37.69% |
International
9.5
%
| 410 | 10.1 % | 529 | 9.5 % | +29.07% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jong-Sik Chun
CEO | Chief Executive Officer | 57 | 09-10-31 |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
Hyeon Kim
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
Chang-Yeong Yang
AUD | Comptroller/Controller/Auditor | 53 | - |
Hye-Jin Hwang
PRN | Corporate Officer/Principal | 55 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Yong-Soo Jung
BRD | Director/Board Member | 54 | - |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,112,502 | 4,508,744 ( 49.48 %) | 0 | 49.48 % |
Company contact information
CJ Bioscience, Inc.
14 Sejong-Daero Grand Central Building B
100-768, Jung-gu
+
http://www.cjbioscience.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
-13.75% | 95.16M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- A311690 Stock
- Company CJ Bioscience, Inc.